At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Crataegus Special Extract WS 1442drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Clinical Trial of a Crataegus Oxycantha Extract in Chronic Heart Failure
National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted Jun 23, 2006·Updated Jun 23, 2006
In Brief
A Phase 3 clinical trial evaluating Crataegus Special Extract WS 1442 for Chronic Heart Failure. Completed, across 1 site.
Detailed Summary
To determine the effect of hawthorn extract 450 mg bid vs. placebo, in addition to standard medical therapy in ambulatory patients with NYHA class II to IV chronic heart failure on submaximal exercise as measured by the 6-minute walk test
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure
CountriesUnited States
CollaboratorsUniversity of Michigan
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2000
Study CompletionMay 2004
First PostedJun 2006
TodayJul 2026
First PostedJun 23, 2006
Enrollment StartJan 1, 2000
Study CompletionMay 1, 2004
TodayJul 2, 2026
Posted 20.0 years ago
Interventions
Crataegus Special Extract WS 1442drug